


Ask a doctor about a prescription for TODACITAN 1.5 mg TABLETS
Package Leaflet: Information for the User
Todacitan1.5 mg EFG Tablets
Cytisine
Read the entire package leaflet carefully before starting to use this medication, as it contains important information for you.
If you have any questions, consult your doctor or pharmacist.
Contents of the Package Leaflet
It helps to quit smoking and to alleviate the anxiety that occurs when quitting smoking. The goal of Todacitan treatment is permanent cessation of the smoking habit.
The use of Todacitan allows for a gradual reduction of nicotine dependence through the relief of withdrawal symptoms.
Do not useTodacitan:
Warnings and Precautions
Consult your doctor or pharmacist before starting to take Todacitan.
Todacitan should be used with caution in cases of ischemic heart disease, heart failure, hypertension, pheochromocytoma (adrenal gland tumor), atherosclerosis (hardening of the arteries), and other peripheral vascular diseases, gastric and duodenal ulcers, gastroesophageal reflux disease, hyperthyroidism (overactive thyroid), diabetes, schizophrenia, renal and hepatic insufficiency.
Only people who have a firm intention to quit smoking should take Todacitan. Using Todacitan without quitting smoking could worsen the adverse effects of nicotine.
Children and Adolescents
Due to limited experience, the medication is not recommended for use in individuals under 18 years of age.
Elderly Population
Due to limited clinical experience, Todacitan is not recommended for use in patients over 65 years of age.
Patients with Renal and Hepatic Insufficiency
There is no clinical experience with Todacitan in patients with renal or hepatic insufficiency; therefore, the medication is not recommended for use in such patients.
Using Todacitan with Other Medications
Inform your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
Do not take Todacitan with anti-tuberculosis medications.
In some cases, as a result of quitting smoking (with or without Todacitan), it may be necessary to adjust the dose of other medications. Such adjustment is particularly important if you are using other medications that contain theophylline (for asthma treatment), tacrine (for Alzheimer's disease), clozapine (for schizophrenia), or ropinirole (for Parkinson's disease treatment). If you are unsure, consult your doctor or pharmacist.
It is currently unknown whether Todacitan can reduce the effectiveness of systemic hormonal contraceptives. If you use systemic hormonal contraceptives, you should add a second barrier method (e.g., condoms).
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
If you are a woman of childbearing potential, you should use effective contraceptive methods. Ask your doctor for advice.
Todacitan is contraindicated during pregnancy and breastfeeding.
Driving and Using Machines
Todacitan has no influence on the ability to drive and use machines.
Quitting Smoking
The effects of the changes that occur in the body as a result of quitting smoking (with or without Todacitan treatment) may alter the mechanism of action of other medications. Therefore, in some cases, it may be necessary to adjust the dose. For more details, see the section "Using Todacitan with Other Medications".
In some individuals, quitting smoking, with or without treatment, has been associated with an increased risk of experiencing changes in thinking or behavior, with feelings of depression and anxiety (including, rarely, suicidal ideation and attempted suicide), and may be related to the worsening of psychiatric disorders. If you have a history of psychiatric disorders, you should discuss this with your doctor.
Follow the administration instructions for this medication exactly as indicated by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.
A pack of Todacitan (100 tablets) is sufficient for a complete treatment course. The treatment duration is 25 days. Todacitan is for oral use and should be taken with an adequate amount of water according to the schedule indicated below.
Treatment Days | Recommended Dose | Maximum Daily Dose |
Days 1-3 | 1 tablet every 2 hours | 6 tablets |
Days 4-12 | 1 tablet every 2.5 hours | 5 tablets |
Days 13-16 | 1 tablet every 3 hours | 4 tablets |
Days 17-20 | 1 tablet every 5 hours | 3 tablets |
Days 21-25 | 1-2 tablets per day | Up to 2 tablets |
You should quit smoking no later than the 5th day of treatment. Do not continue smoking during treatment, as this could worsen adverse reactions. If treatment fails, it should be interrupted and may be resumed after 2 or 3 months.
If you take more Todacitan than you should
Symptoms of nicotine poisoning are observed in case of Todacitan overdose. Overdose symptoms include, among others, general malaise, nausea, vomiting, increased heart rate, blood pressure fluctuations, respiratory problems, blurred vision, convulsions.
If you experience any of the symptoms described or any other symptom not mentioned in this package leaflet, stop taking Todacitan and consult your doctor or pharmacist.
If you forget to take Todacitan
Do not take a double dose to make up for forgotten doses.
If you interrupt treatment with Todacitan
If you have any further questions on the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
These side effects may occur with certain frequencies, which are defined as follows:
Very Common (may affect more than 1 in 10 users):changes in appetite (mainly increased), weight gain, dizziness, irritability, mood changes, anxiety, increased blood pressure (hypertension), dry mouth, diarrhea, skin rash, fatigue, sleep disorders (insomnia, somnolence, lethargy, abnormal dreams, nightmares), headaches, increased heart rate, nausea, altered taste, heartburn, constipation, vomiting, abdominal pain (especially in the upper abdomen), muscle pain.
Common (may affect between 1 and 10 in 100 users):difficulty concentrating, slow heart rate, abdominal distension, tongue burning, general malaise.
Uncommon (affect between 1 and 10 in 1000 users):feeling of heaviness in the head, decreased libido, tearing, dyspnea, increased sputum, excessive salivation, sweating, decreased skin elasticity, fatigue, increased serum transaminase levels.
Most of the side effects mentioned occur at the beginning of treatment and disappear during its duration. These symptoms can also be a consequence of quitting smoking (withdrawal symptoms) and not due to treatment with Todacitan.
Reporting Side Effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: www.notificaRAM.es
By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Store below 25°C. Store in the original packaging to protect from light and moisture.
Do not use this medication after the expiration date indicated on the packaging. The expiration date is the last day of the month indicated.
Do not dispose of any medication through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition ofTodacitan
Appearance of the Product and Package Contents
Todacitan is a white, round, and biconvex tablet with a diameter of 6 mm.
PVC/PCTFE/aluminum or PVC/PE/PVDC/aluminum blisters placed in a cardboard box containing 100 tablets.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Aflofarm Farmacja Polska Sp. z o.o.
Partyzancka 133/151
95-200 Pabianice
Poland
tel. (42) 22-53-100
Local Representative
Aflofarm Spain S.L.U.,
Avd. Diagonal, 327, 4º2ª B2,
08009 Barcelona, Spain
Telephone: 931 205 432,
Manufacturer:
Aflofarm Farmacja Polska Sp. z o.o.
Szkolna 31
95-054 Ksawerów
Poland
Date of the Last Revision of this Package Leaflet: 07/2023
Detailed information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of TODACITAN 1.5 mg TABLETS in October, 2025 is around 111.09 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TODACITAN 1.5 mg TABLETS – subject to medical assessment and local rules.